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Abstract
Introduction. The aim of the study was to assess a presence of peripheral arterial disease risk factors in 
patients with symptomatic femoral and iliac lesions treated with use of Jaguar and Supera nitinol stents and to 
estimate potential relation between these factors and reintervention rate. 
Material and methods. The study group consisted of 60 patients between 46 and 85 years of age who 
presented with typical symptoms of intermittent claudication or critical limb ischemia and underwent percuta-
neous transluminal angioplasty with stenting. We examined and divided group into two subgroups — patients 
who experienced or did not experience need of reintervention in treated lesion.
Results. During the follow-up 24 (40%) of patients underwent reintervention in treated artery due to re-
current symptoms of disease. Need of target lesion revascularization occurred more frequent in patients with 
hypertension (OR = 2.5), patient older than 68 (OR = 1.75) and smokers (OR = 1.75). Patency of all three 
arteries below knee protected from reintervention. 
Conclusions. Jaguar and Supera self-expanding nitinol stents has several advantages and its use were char-
acterized by high procedural success and moderate frequency of reintervention correlated to some clinical 
findings like hypertension. Further studies are necessary to estimate factors disturbing and interfering with 
long-term patency.
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Introduction
Peripheral arterial disease (PAD) is the third lead-
ing cause of cardiovascular morbidity after myocardial 
infarction and stroke and is growing problem of de-
veloping as well as developed countries (Table 1) [1]. 
Its main reason is atherosclerosis which once initiat-
ed evolves, accelerated by both numerous well known 
risk factors and also newly understood inflammatory 
mechanisms [2]. Increasing life expectancy and growing 
diabetes mellitus incidence rate causes that peripheral 
arterial disease or lower limb ischemia (LLI) is not only 
diagnosed more often in recent times but also influ-
enced by diabetes mellitus may be associated with an 
increased mortality rate, which is shown in Figure 1 [3]. 
Apart from intensive risk factors modification, which 
is obligatory basis of therapy, pharmacologic interven-
tions and supervised exercise programs in many cases 
early interventional treatment — surgical or endovas-
cular — is necessary after diagnosis [4–6].
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In spite of advances in invasive treatment and signif-
icant improvement of optimal pharmacotherapy with 
statin mortality among patients hospitalized due to 
lower limb ischemia seems to remain unchanged [7–9].
Methods of endovascular treatment have evolved 
in last years from simple balloon angioplasty through 
balloon-expandable stents implantation to use of nitinol 
self-expanding stents. First generation of stents did not 
meet the expectations for better long term results com-
pared to PTA alone. Self-expanding stents inspire hope of 
better long term results defined as permanent recovery 
from symptoms with lower reinterventions rate.
However, the significant prevalence of elective niti-
nol stent implantation strategy over PTA alone has not 
been proved and better outcomes after routine use of 
nitinol stents are controversial [10–14]. In spite of this 
fact a trend toward wide implantation of self-expanding 
nitinol stents is observed among operators performing 
superficial femoral artery (SFA) interventions. 
The ideal stent for use in superficial femoral artery 
should combine attributes like flexibility allowing to 
use in cross-over technique, radial force and in pop-
liteal region also significant bending- and compression 
resistance. Those criteria seems to be fulfilled by Jaguar 
(Balton) and Supera (Abott) stents (Fig. 2). First listed, 
Jaguar not only can be modified during intravascular 
deployment, but safely withdrawn and repositioned 
during the same medical procedure as well and thus 
enables precise positioning and deployment [15]. Su-
pera with its interwoven nitinol design seems to be very 
compression- and movement-resistant which prevents 
fractures in distal parts of SFA and popliteal region. 
The aim of our study was to assess the presence of 
peripheral arterial disease risk factors in patients with 
symptomatic femoral and iliac lesions treated with use 
of Jaguar and Supera nitinol stents, but also to estimate 
potential relation between these factors and reinter-
vention rate. Additionally, we checked whether some 
significant differences between stents will appear and 
last, we also tried to investigate possible relationships 
between reinterventions and some clinical or angio-
graphical conditions. We considered particular char-
acteristics significant from procedures’ point of view 
like size of implanted stent, number of patent arteries 
below the knee or dual antiplatelet therapy use. 
Material and methods
Over a period of three years (from 2012 to 2015) 
among all patients with symptomatic peripheral arte-
rial disease hospitalized in the Department of Vascular 
Surgery and Angiology Medical University of Lublin, 
Table 1. Estimated number of people living with peripheral artery disease in high-income countries, low-income and middle-income 
countries, and worldwide in the years 2000 and 2010, and the rate of change from 2000 to 2010 — data from literature [1]
People living with peripheral  
artery disease in year 2000  
(thousands)
People living with peripheral  
artery disease in 2010 (thousands)
Rate of change  
(2000–2010)
High- 
-income  
countries
Low-income 
and middle-
-income 
countries
Worldwide High- 
-income  
countries
Low-income 
and middle-
-income 
countries
Worldwide High- 
-income  
countries
Low-income 
and middle-
-income 
countries
Worldwide
25–29 years 2311 10 756 13 068 2381 12 037 14 419 3·02% 11·91% 10·34%
30–34 years 2803 11  469 14  272 2760 12  343 15  103 −1·52% 7·62% 5·82%
35–39 years 3486 11  247 14  733 3343 13  776 17  119 −4·12% 22·49% 16·19%
40–44 years 4071 11  138 15  209 3938 14  707 18  645 −3·28% 32·05% 22·59%
45–49 years 4528 11  408 15  936 4851 14  354 19  205 7·14% 25·83% 20·51%
50–54 years 4907 9902 14  808 5503 14  100 19  603 12·15% 42·40% 32·37%
55–59 years 4530 9111 13  641 5948 14  170 20  118 31·31% 55·53% 47·49%
60–64 years 5342 9074 14  416 6242 11  787 18  029 16·85% 29·90% 25·06%
65–69 years 5287 8416 13  704 5547 10  124 15  670 4·90% 20·29% 14·35%
70–74 years 5594 6953 12  547 6043 9020 15  063 8·02% 29·73% 20·05%
75–79 years 4808 4960 9768 5370 7012 12  382 11·68% 41·36% 26·75%
80–84 years 3107 3015 6123 4723 4396 9118 51·98% 45·77% 48·92%
85–89 years 2246 1411 3658 3028 2087 5115 34·80% 47·86% 39·84%
≥ 90 years 1174 544 1717 1611 864 2474 37·22% 58·82% 44·09%
Total 54  195 109  405 163  600 61  287 140  775 202  062 13·08% 28·67% 23·51%
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Figure 1. Meta-analysis (random effects model) testing the association between diabetes and all-cause mortality in (A) all studies 
with peripheral artery disease, (B) prospective studies with performed multivariate analysis without critical limb ischemia, (C) all 
studies with critical limb ischemia, and (D) Caucasian studies with critical limb ischemia. Data from literature [3]
Figure 2. Jaguar and Supera nitinol self-expanding stents
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who underwent percutaneous transluminal angioplas-
ty (PTA) and stenting we chose all treated with two 
kinds of self-expanding nitinol stents: Jaguar (Balton) 
and Supera (Abbott). The study group consisted of 60 
patients — 47 males and 13 females aged from 46 to 85 
(average 66.77) and were subdivided into stages of Fon-
taine classification. The group was composed of both 
elective and also more urgent patients with critical limb 
ischemia. The retrospective analysis based on medical 
records was performed. Diagnosis of peripheral arterial 
disease was based on typical anamnesis and ultrasound 
examination with Doppler. Indication for endovascular 
treatment and final qualification was confirmed directly 
after arteriography. All interventions were performed 
under local anesthesia with use of 5–10 mL 2% lido-
caine solution, in most cases through femoral access, 
using 6 F introducers. After arteriography and balloon 
angioplasty in all patients nitinol stent Jaguar or Supera 
was implanted. There were no complications and no 
need to surgical conversion.
Whole study group was monitored for the pres-
ence of cardiovascular risk factors and also for po-
tential restenosis risk factors as diabetes mellitus, 
chronic kidney disease and diameter or length of 
implanted stents. Retrospectively we detected all 
patients with reintervention in treated artery and 
examined potential relevance to risk factors and 
some angiographical findings. We compared two 
subgroups: patients who experienced and did not 
experience reintervention. 
Results
In 36 patients (60%) symptoms of Fontaine IIb stage 
were present. Critical limb ischemia (CLI) defined as 
the presence of ischemic rest pain (Fontaine stage III) 
or ulcers or gangrene (Fontaine stage IV) was present 
respectively in 14 (23%) and 9 (15%) patients, while 
only one patient (1.67%) was in Fontaine stage IIa. 
In angiography patency of all three vessels below 
the knee was observed in 26 patients (43%), two 
patent arteries in next 16 (26.7%) and one vessel also 
in 16 patients (26.7%). Lack of any patent artery was 
noted in one patient (3.3%). Dual antiplatelet therapy 
at discharge received 54 patients (90%), whereas one 
antiplatelet drug was prescribed to another 6 patients 
(10%). 
After arteriography and balloon angioplasty in 33 
patients (55%) nitinol stent Jaguar and in 27 patients 
(45%) Supera were implanted. Both of these subgroups 
did not show any significant differences in demograph-
ics, as well as cardiovascular risk factors burden. Sub-
groups were also similar in regard to dual antiplatelet 
therapy (p = 0.56) and number of patent peripheral 
arteries (p = 0.55). 
Repeat target lesion revascularization was per-
formed in 14 patients (42%) who received Jaguar and 
in 10 (37%) who received Supera stents. Therefore, 
none of these stents turned to be related to higher or 
lower reintervention rate (p = 0.43). Sizes of implanted 
stents are shown in Figure 3 and 4.
Figure 3. Length of stents used in study group
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In the analysis whole study group was divided into 
2 subgroups — 24 patients (40%) who underwent 
reintervention and 36 (60%) without need of repeated 
target lesion revascularization. Mean time to reinter-
vention was 5.91 months (± 4.43 months), whereas 
follow-up ranged from 1 to 42 months (mean 24.5 
months).
Incidence of peripheral arterial disease risk factors 
in subgroups of patients with or without reintervention, 
as well as some procedural and periprocedural data for 
both groups were collected and analyzed (Table 2 and 3). 
Among cardiovascular risk factors hyperlipidemia, 
type 2 of diabetes mellitus and chronic kidney disease 
were not associated with reintervention, whereas 
arterial hypertension was associated with a higher risk 
of target lesion revascularization (OR = 2.5). Reinter-
vention occurred more often also in patients older than 
68 (OR = 1.75), and smokers (OR = 1.75). 
Figure 4. Diameter of stents used in study group
Table 2. Comparison of groups with and without reinterventions — risk factors
Reintervention
p OR 95% CINO YES
n % n %
Sex
F 8 22.22 5 20.83
0.5805 1.09 0.31 3.83
M 28 77.78 19 79.17
Age < 68 20 55.56 10 41.67
0.2918 1.75 0.62 4.97
> 68 16 44.44 14 58.33
Arterial hypertension
No 20 55.56 8 33.33
0.0910 2.50 0.85 7.31
Yes 16 44.44 16 66.67
Diabetes mellitus type 2
No 28 77.78 17 70.83
0.5428 1.44 0.44 4.69
Yes 8 22.22 7 29.17
Chronic kidney disease
No 31 86.11 21 87.50
0.5985 0.89 0.19 4.11
Yes 5 13.89 3 12.50
Smoking
No 20 55.56 10 41.67
0.2918 1.75 0.62 4.97
Yes 16 44.44 14 58.33
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Interestingly, need of reintervention in our group 
was not correlated with a diameter or length of im-
planted stents. Fontaine stage also did not determine 
intervention rate, while patency of all three arteries 
below the knee was associated with a significantly lower 
reintervention risk (Table 4). 
Additionally, in Cox regression model no independ-
ent variables were shown, which were responsible 
for need of reintervention (c2 = 13.96; p = 0.2355) 
(Table 5).
Discussion
Since peripheral arterial disease may be asympto-
matic for months and years, it is often diagnosed in 
advanced stage with observed diffuse, occlusive and 
multifocal lesions, which results in worse endovascular 
treatment outcomes, when compared to less advanced 
forms (TASC A-B). Patients with iliac and femoral 
lesions represent substantial proportion of patients 
with signs of peripheral arterial disease, because such 
localization determines more severe symptoms and 
enables early diagnosis. This was also confirmed in 
our study group, which included really symptomatic 
patients — only one of them was in Fontaine stage IIa.
Endovascular procedures are widely accepted 
methods of treating patients with iliac and femoral 
TASC A-B lesions [4]. Recent data show, that many 
of more complex lesions (TASC C-D) can be safely 
treated with primary self-expanding nitinol stents with 
acceptable long-term primary patency rates [16]. On 
the other hand many studies including one with group 
of 2096 patients and 2601 treated limbs reported lower 
technical success and higher complications rate of aor-
to-iliac interventions in TASC D lesions in comparison 
to TASC A-C lesions [17]. 
As mentioned above evidence on superiority of pri-
mary self-expanding nitinol stents implantation strategy 
over methods based on balloon angioplasty with option-
al secondary stenting is uncertain. However, there are 
more and more papers providing this assumption and 
primary use of those devices seems to be dominant end-
ovascular way of treatment in the nearest future. Dick 
et al showed a lower restenosis rate after self-expanding 
Table 4. Comparison of groups with and without reinterventions
Reintervention
pNO YES
n % n %
Fontaine stage
IIa 1 2.78 0 0.00
0.8279
IIb 21 58.33 15 62.50
III 9 25.00 5 20.83
IV 5 13.89 4 16.67
Patent arteries below the knee
0 1 2.78 1 4.17
< 0.05
1 11 30.56 5 20.83
2 5 13.89 11 45.83
3 19 52.78 7 29.17
Table 3. Comparison of groups with and without reinterventions — procedural and periprocedural data
Reintervention
p OR 95% CINO YES
n % n %
Stent
Jaguar 19 52.78 14 58.33
0.6717 0.80 0.28 2.26
Supera 17 47.22 10 41.67
Lenght
< 120 14 38.89 10 41.67
0.8296 0.89 0.31 2.55
> 120 22 61.11 14 58.33
Diameter
< 6 15 41.67 8 33.33
0.5154 1.43 0.49 4.19
> 6 21 58.33 16 66.67
Antiplatelet drugs
1 3 8.33 3 12.50
0.4556 0.64 0.12 3.45
2 33 91.67 21 87.50
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Table 5. Cox regression model data
Beta Standard 
error
t-value Exponent 
beta
Wald statist. p
Sex –0.41 0.66 –0.61 0.67 0.38 0.5402
Stent lenght 0.01 0.01 0.88 1.01 0.78 0.3772
Stent diameter 0.51 0.37 1.37 1.66 1.89 0.1693
Fontaine class –0.48 0.27 –1.77 0.62 3.14 0.0766
Age –0.05 0.04 –1.35 0.95 1.81 0.1781
Arterial hypertension –1.16 0.62 –1.87 0.31 3.50 0.0613
Diabetes mellitus type 2 –0.84 0.68 –1.24 0.43 1.55 0.2137
Smoking –0.59 0.60 –1.00 0.55 0.99 0.3195
Chronic kidney disease 0.19 0.77 0.25 1.21 0.06 0.7996
Patent arteries below the knee –0.37 0.35 –1.07 0.69 1.13 0.2868
Antiplatelet therapy –1.41 0.87 –1.62 0.24 2.62 0.1055
nitinol stent implantation in SFA lesion over PTA after 6 
months, and further benefits were observed after one 
year [13]. Similar results were reported by Schillinger 
et al. [14]. Iliac lesions treatment were also a subject of 
numerous trials and some meta-analyses, which showed 
a prevalence of primary stenting over PTA alone, in 
both hemodynamic parameters and clinical symptoms 
classifications [18–20]. The benefits were also shown 
in self-expanding stents studies [21, 22]. 
A placement of stents is accepted therapy for iliac 
and femoral artery occlusive disease. Selective pro-
visional stenting to salvage iliac lesions after failed or 
unsatisfactory PTA due to elastic recoil, flow-limiting 
dissection or residual gradient, is well established. A pri-
mary stent implantation strategy offers additional bene-
fits, including improved technical success and ability to 
treat complex disease. Moreover, such complications 
like flow-limiting dissection and acute artery closure 
are significantly decreased, and long-term restenosis 
rates appear to be significantly improved. 
A further trials are necessary to establish role of 
novel devices like drug eluting stents in achieving du-
rable results and confirm present short-term observa-
tions [23, 24]. Some promising techniques for instance 
common femoral artery angioplasty with optional 
bifurcation treatment requires validation and appear 
to be interesting option and alternative to surgery way 
of treatment [25]. 
In our study group a very high success rate of the 
procedures reflects and confirms the advantages of 
implanted stents — 100% procedures was finished 
with stent implantation and none of patients required 
urgent surgical intervention as a result of complication. 
However, we observed high risk of reintervention 
rate in our study group (40%) despite the fact, that 
follow-up was based on symptoms, not on elective ar-
teriography as an element of study. This means, that the 
restenosis rate might even be higher than 40%, if all pa-
tients would undergo arteriography. Some authors also 
report high restenosis and reintervention rate. Yu et. al 
demonstrated disappointing results of SFA stenting with 
bare metal stents with the primary and secondary paten-
cy rates at two years respectively 22% and 58% [26]. 
Factors correlated with reinterventions in this study 
were: diabetes mellitus [HR (hazard ratio) = 2.50; 
p = 0.039], long lesions > 8 cm (HR = 2.62; p = 0.04) 
and TASC C-D lesions (HR = 2.05; p = 0.03), but 
chronic kidney disease showed trend toward higher 
intervention rate (HR = 1.72).
We noticed a large risk factors burden in our study 
group — in particular over 98% of patients had a lipid 
disorders history and 100% patients were treated 
with statin and aspirin. We examined influence of 
various factors and did not confirm the correlation 
between diabetes mellitus and higher reintervention 
rate, reported in other previous studies [26, 27]. 
We did not observe also relation of chronic kidney 
disease to reinterventions, which was comparable to 
other studies [27]. On the other hand, surprising was 
the observation, that neither diameter nor length of 
implanted stents affected reintervention rate. What is 
interesting, arterial hypertension turned to be asso-
ciated with higher risk of reintervention (OR = 2.5) 
and smoking or age older than 68 demonstrated 
a trend toward higher risk of repeated target lesion 
revascularization (OR = 1.75).
Finally, as we expected, general rule that adequate 
inflow and appropriate outflow are required to keep 
revascularized segment functioning was also confirmed 
in our study. Presence of all three patent vessel below 
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the knee was significant factor preventing from re-in-
tervention (p < 0.05).
Conclusions
1. There was no difference between both stents in 
terms of target lesion revascularization rate.
2. Arterial hypertension was associated with higher 
risk of reintervention and smoking or older age 
demonstrated a trend toward higher risk of repeat-
ed target lesion revascularization.
3. Three patent arteries below the knee was asso-
ciated with lower re-intervention rate, but we 
did not observed the size of the stents impact on 
reintervention rate.
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